# **Munich Cancer Registry**



- Incidence and Mortality
- Selection Matrix
- Homepage
- Deutsch

## ICD-10 C07, C08: Salivary gland cancer

Year of diagnosis	1988-1997	1998-2014
Patients	155	683
Diseases	155	684
Cases evaluated	143	492
Creation date	03/02/2016	
Export date	12/23/2015	
Population	4.64 m	


### Survival



Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

http://www.tumorregister-muenchen.de/en/facts/surv/sC0708E-ICD-10-C07-C08-Salivary-gland-cancer-survival.pdf




**Figure 1a.** Relative survival of patients with salivary gland cancer by period of diagnosis. Included in the evaluation are 632 cases diagnosed between 1988 and 2014.

The survival results of the SEER program (Surveillance, Epidemiology, and End Results) of the American National Cancer Institute (NCI) are summarized as the period of diagnosis from 1998 to 2011, and are represented by gray diamonds in order to facilitate comparisons between MCR and SEER.

The presented survival curves are derived from clinical records with valid follow-up informations, which means that death certificate cases (DCO) cases are omitted from the analysis. With this one restriction, the MCR has provided populationbased statistics since 1998, collecting data on all cancer cases in the region of southern Bavaria. Historical data of previous time periods can be heavily selected, therefore, univariate survival comparisons of the presented time periods must be carefully considered. Nonetheless, all calculable survival curves are depicted to facilitate the comparison of long time follow-up analyses of relative survival between particular cancers.

	F	Period	gnosis	;		
	1988-	1997	1998-	2006	200	)7+
	n=1	142	n=2	214	n=2	276
Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
0	100.0	100.0	100.0	100.0		100.0
1	88.4	90.9	89.2	91.3	89.3	91.8
2	78.7	83.5		81.1	83.8	88.3
3	70.6	76.8	70.8	75.8	73.7	79.9
4	63.8	71.1	66.4	72.6	65.8	73.5
5	56.9	64.9	63.9	70.8	61.0	69.3
6	55.4	63.8	61.3	69.6	57.9	66.8
7	51.6	62.2	59.3	68.9	51.0	59.2
8	49.4	60.5	55.1	65.3		
9	47.1	59.3	53.9	64.6		
10	44.7	57.6	52.1	63.6		
11	40.8	54.2	49.3	61.3		
12	40.0	54.1	46.5	59.2		
13	38.4	53.0	45.3	58.3		
14	37.6	52.3	45.3	57.7		
15	33.5	48.3	45.3	57.1		
16	32.7	47.7				
17	32.7	47.7				
18	31.0	46.6				
19	28.1	43.4				
20	27.0	43.1				

**Table 1b.** Observed (obs.) and relative (rel.) survival of patients with salivary gland cancer by period of diagnosis for period 1988-2014 (N=632).




**Figure 2a.** Survival of patients with salivary gland cancer by gender. Included in the evaluation are 632 cases diagnosed between 1988 and 2014.

		C	Gender	r			
		Ma	ale	Ferr	nale		
		n=3	337	n=2	n=295		
	Years	obs. %	rel. %	obs. %	rel. %		
	0	100.0	100.0	100.0	100.0		
	1	85.3	87.8	93.3	95.9		
	2	77.1	81.3	84.1	88.7		
	3	68.3	74.0	76.3	82.2		
	4	60.8	67.6	71.5	79.1		
	5	57.4	65.1	65.8	74.3		
	6	56.1	64.0	62.3	72.0		
	7	52.5	62.5	59.1	69.4		
	8	49.1	59.7	55.4	67.0		
	9	47.9	58.8	53.4	65.5		
	10	45.9	57.9	51.1	64.1		

**Table 2b.** Observed (obs.) and relative (rel.) survival of patients with salivary gland cancer by gender for period 1988-2014 (N=632).






**Figure 3a.** Relative survival of patients with salivary gland cancer by age category. Included in the evaluation are 632 cases diagnosed between 1988 and 2014.

			Age category						
		0-49			60-69	9 yrs	70+ yrs		
		n=1			07	n=1	n=151		231
	Years	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %	obs. %	rel. %
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	97.1	96.7	95.0	95.0	89.8	91.0	81.2	86.5
	2	93.8	93.4	85.7	86.4	84.2	86.5	67.6	77.0
	3	88.6	88.9	80.3	81.4	77.0	80.5	55.5	67.2
	4	85.8	86.3	76.7	78.1	72.2	76.9	45.1	58.8
	5	85.8	86.0	71.2	72.5	67.1	72.0	38.9	54.4
	6	85.8	85.6	67.1	69.0	63.5	70.0	36.9	53.4
	7	83.2	83.8	65.5	68.3	59.6	67.5	32.5	53.3
	8	81.7	82.7	63.9	67.7	54.9	63.7	27.7	49.4
	9	80.0	81.4	63.9	67.7	54.9	63.7	24.4	46.5
	10	80.0	81.1	63.9	67.7	50.5	61.2	21.8	44.7

**Table 3b.** Observed (obs.) and relative (rel.) survival of patients with salivary gland cancer by age category for period 1988-2014 (N=632).






**Figure 4a.** Relative survival of patients with salivary gland cancer by TNM staging. For 526 of 632 cases diagnosed between 1988 and 2014 valid data could be obtained for this item. For a total of 522 cases an evaluable classification was established. The accumulated percentage exceeds the 100% value because patients are potientially considered in more than one subgroup. The grey line represents the subgroup of 110 patients with missing values regarding TNM staging (17.4% of 632 patients, the percent values of all other categories are related to n=522).

	TNM staging														
		Т	1	Т	2	Т3	+4	Ň	0	N	+	N	Х	NA/N	NOS
		n=1	29	n=1	165	n=2	211	n=3	305	n=1	73	n=	23	n=1	10
Y	'ears	obs. %	rel. %												
	0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
	1	100.0	100.0	96.9	98.9	80.4	83.4	93.9	96.2	85.9	88.5	90.9	88.2	80.8	83.0
	2	95.5	97.5	88.3	92.5	71.1	75.7	90.4	94.7	70.5	74.3	81.3	80.2	69.1	73.2
	3	90.9	94.8	79.4	84.9	59.7	65.8	83.5	89.6	58.2	63.1			64.2	69.9
	4	86.7	91.8	71.4	78.2	51.7	59.0	79.8	87.6	45.8	51.4			61.1	68.0
	5	84.4	89.8	67.2	75.3	46.1	53.7	76.1	85.1	41.4	47.0			55.5	63.4
	6	83.2	89.7	64.6	73.9	43.9	52.3	74.6	84.3	39.6	45.7			52.0	60.7
	7	81.6	89.7	58.7	69.2	40.8	50.1	70.8	82.6	36.3	43.5			49.4	59.3
	8	80.0	89.7	55.3	66.5	37.0	47.1	67.7	80.4	32.4	40.5			43.8	53.2
	9	78.4	88.9	55.3	66.5	35.0	45.4	66.4	79.9	30.9	39.5			40.5	49.2
	10	73.3	86.2	54.0	66.5	33.9	44.4	62.7	77.1	30.9	39.2			38.8	48.2

**Table 4b.** Observed (obs.) and relative (rel.) survival of patients with salivary gland cancer by TNM staging for period 1988-2014 (N=1,006).


ICD-10 C07, C08: Malignant neoplasm of salivary glands



**Figure 5a.** Time to first progression of 462 patients with salivary gland cancer diagnosed between 1998 and 2014 (M0 only in solid cancers) estimated by cumulative incidence function (CI, solid line) accounting for death as competing risk and by inverse Kaplan-Meier estimate (1-KM, dashed line). The frequency of events may be underestimated due to underreporting.

		Г	Type of progr	ession	
		Any type (CI)	Any type (1-KM)	Locoreg. relapse (CI)	Locoreg. rel. (1-KM)
		n=462	n=462	n=462	n=462
	Years	%	%	%	%
	0	0.0	0.0	0.0	0.0
	1	16.3	16.6	6.2	6.7
	2	25.9	26.8	10.5	11.6
	3	30.4	31.7	14.2	16.2
	4	32.4	34.0	15.1	17.4
	5	33.7	35.6	16.0	18.9
	6	34.5	36.6	16.4	19.4
	7	35.3	37.7	16.4	19.4
	8	36.3	39.0	16.9	20.2
	9	36.9	39.8	17.4	21.2
	10	37.5	40.8	17.4	21.2

**Table 5b.** Time to first progression of patients with salivary gland cancer for period 1998-2014 (N=462).




**Figure 5c.** Observed post-progression survival of 136 patients with salivary gland cancer diagnosed between 1998 and 2014. These 136 patients with documented progression events during their course of disease represent 28.2% of the totally 482 evaluated cases (incl. M1, n=20, 4.1%). Patients with cancer relapse documented via death certificates only were excluded (n=39, 8.1%). Multiple progression types on different sites are included in the evaluation even when not occuring synchronously.

Medical record documentation often lacks the linguistic severity to distinguish between local relapse, regional lymph node metastasis and distant spread in solid cancers. Frequently, the statement "not specified" is the only information in registries regarding relapse of the disease. The category "Any type" denotes all cases who suffered from at least one relapse during the course of disease (incl. primary M1-status). Although, the real number of relapsed patients is likely to be much higher. The accumulated percentage of patients with local relapse or distant metastasis exceeds the 100% value because patients are potientially considered in more than one subgroup.

Type of progression				
-		Locoregional relapse		
	n=136	n=75		
Years	%	%		
0	100.0	100.0		
1	63.9	73.0		
2	44.9	55.3		
3	37.7	48.9		
4	32.8	45.5		
5	31.7	43.7		
6	27.1	37.8		
7	25.5			

**Table 5d.** Observed post-progression survival of patients with salivary gland cancer for period 1998-2014 (N=136).



**Figure 5e.** Observed post-progression (distant metastasis) survival of 115 patients with salivary gland cancer diagnosed between 1988 and 2014 by period of progression.

	Period o	of progressio	n
	1988-1997	1998-2006	2007+
	n=16	n=33	n=66
Years	%	%	%
0	100.0	100.0	100.0
1		60.6	59.9
2			39.4

**Table 5f.** Observed post-progression (distant metastasis) survival of patients with salivary gland cancer for period 1988-2014 by period of progression (N=115).

#### Shortcuts

NCI National Cancer Institute, USA   SEER Surveillance, Epidemiology, and End Results, USA   UICC Union for International Cancer Control, Geneva   DCO Death certificate only Death certificate provides the only notification to the registry.   NA Not available Nos   NOS Not otherwise specified Overall/Observed survival   OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate)   Date of entry: diagnosis Event: death from any cause   RS Relative survival Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival   Assembled survival Assembled chart of observed, expected, relative survival   CS Conditional survival Survival probability under the condition of surviving a given period of time   TTP Time to progression Time to first progression / relapse   Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence distant metastasis or unspecified progression		
UICC Union for International Cancer Control, Geneva   DCO Death certificate only Death certificate provides the only notification to the registry.   NA Not available Death certificate provides the only notification to the registry.   NA Not available Death certificate provides the only notification to the registry.   NA Not available Overall/Observed survival (Kaplan-Meier estimate)   Date of entry: diagnosis Event: death from any cause   RS Relative survival Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival   AS Assembled survival Assembled chart of observed, expected, relative survival   CS Conditional survival Survival probability under the condition of surviving a given period of time   TTP Time to progression Time to first progression / relapse   Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
DCODeath certificate onlyDeath certificate provides the only notification to the registry.NANot availableDeath certificate provides the only notification to the registry.NOSNot otherwise specifiedOverall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any causeRSRelative survivalSurvival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survivalASAssembled survivalAssembled chart of observed, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
NA Not available   NOS Not otherwise specified   OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause   RS Relative survival Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival   AS Assembled survival Assembled chart of observed, expected, relative survival   CS Conditional survival Survival probability under the condition of surviving a given period of time   TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
NA Not available   NOS Not otherwise specified   OS Overall/Observed survival Overall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any cause   RS Relative survival Survival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survival   AS Assembled survival Assembled chart of observed, expected, relative survival   CS Conditional survival Survival probability under the condition of surviving a given period of time   TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
NOSNot otherwise specifiedOSOverall/Observed survivalOverall/Observed survival (Kaplan-Meier estimate) Date of entry: diagnosis Event: death from any causeRSRelative survivalSurvival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survivalASAssembled survivalAssembled chart of observed, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence	ation to the regis	stry.
OSOverall/Observed survival Date of entry: diagnosis Event: death from any causeRSRelative survivalSurvival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survivalASAssembled survivalAssembled chart of observed, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
RSRelative survivalDate of entry: diagnosis Event: death from any causeRSRelative survivalSurvival compared to "general population", ratio of observed to expected survival (Ederer II method), reflecting cancer specific survivalASAssembled survivalAssembled chart of observed, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
ASAssembled survivalratio of observed to expected survival (Ederer II method), reflecting cancer specific survivalASAssembled survivalAssembled chart of observed, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence	estimate)	
CSConditional survivalobserved, expected, relative survivalCSConditional survivalSurvival probability under the condition of surviving a given period of timeTTPTime to progressionTime to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		' <b>,</b>
TTP Time to progression TTP Time to progression Time to first progression / relapse Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrence		
Date of entry: diagnosis Event: (progression / relapse): first local-, lymph node recurrenc	surviving	
		currence,
1-KM 1 minus Kaplan-Meier estimator ("inverse" Kaplan-Meier estimator)		
CI Cumulative incidence Death as competing risk (according to Kalbfleisch und Prentice)	Ibfleisch und Pre	rentice)
PPS Post-progression survival Survival since first progression / relapse (Kaplan-Meier estimate Date of entry (progression / relapse): first local-, lymph node recurrence, distant metastasis or unspecified progression Event: death from any cause	local-, lymph no	ode

#### **Recommended Citation**

Munich Cancer Registry. Survival ICD-10 C07, C08: Salivary gland cancer [Internet]. 2016 [updated 2016 Mar 2; cited 2016 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/surv/sC0708E-ICD-10-C07-C08-Salivary-gland-cancer-survival.pdf

#### Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

#### Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

### Index of figures and tables

Fig./Tb	bl.	Page
1a	Relative survival by period of diagnosis (chart)	2
1b	Survival by period of diagnosis (table)	3
2a	Survival by gender (chart)	4
2b	Survival by gender (table)	4
3a	Relative survival by age category (chart)	5
3b	Survival by age category (table)	5
4a	Relative survival by TNM staging (chart)	6
4b	Survival by TNM staging (table)	6
5a	Time to first progression (chart)	7
5b	Time to first progression (table)	7
5c	Observed post-progression survival (chart)	8
5d	Observed post-progression survival (table)	8
5e	Observed post-progression survival by period of progression (chart)	9
5f	Observed post-progression survival by period of progression (table)	9